MedTrace Logo

Cancer of the Pancreas Screening Study (CAPS 3)

NCT00438906 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-06-18

No results posted yet for this study

Summary

The purpose of this study is to find the best and most sensitive screening modality (CT, MRI, EUS)for very small pre-cancerous pancreatic lesions and to treat these small lesions before they turn into cancer. Another purpose of this study is to search for common markers on DNA that would increase the chance of someone developing pancreatic cancer, and locate proteins in pancreatic juice that indicate tumor development.

Conditions

  • Pancreatic Neoplasm
  • Peutz-Jeghers Syndrome

Interventions

PROCEDURE

Biopsy, Fine Needle Aspiration (FNA)

If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.

DRUG

Secretin (human synthetic) - ChiRhoClin

Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.

Sponsors & Collaborators

  • Lustgarten Foundation

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Marcia I. Canto, M.D. · Johns Hopkins University

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00438906 on ClinicalTrials.gov